H.C. Wainwright Reiterates Buy Rating on ProQR Therapeutics N.V. (PRQR)

August 17, 2026 6:52 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on ProQR Therapeutics N.V. (NASDAQ: PRQR).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found